All In Biotech

Drug Trial Radar · NCT05798520

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Jul 25, 2023

Primary completion

Feb 10, 2026

Study completion Feb 10, 2026

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.

Conditions

  • Relapsing Forms of Multiple Sclerosis

Interventions

  • BIIB091Drug

    Administered as specified in the treatment arm.

  • DRFDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Adverse Events (AEs)Time frame: Day 1 up to Week 50
  2. Part 1: Number of Participants With Serious Adverse Events (SAEs)Time frame: From signing the informed consent form (ICF) to Week 50
  3. Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) LesionsTime frame: Week 8 to Week 16

Locations

77 sites in 10 countries. Site status is shown where the registry gives one.

  • HonorHealth Neurology

    Scottsdale, Arizona

  • Alta Bates Summit Medical Center

    Berkeley, California

  • University of California at Irvine Medical Center

    Orange, California

  • University of Colorado School of Medic

    Aurora, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Vero Beach Neurology and Research Institute

    Vero Beach, Florida

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • International Neurorehabilitation Institute

    Lutherville, Maryland

  • Washington University

    St Louis, Missouri

  • Holy Name

    Teaneck, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • South Shore Neurologic Associates, P.C.

    Patchogue, New York

  • Wake Forest University - School of Medicine - Central

    Winston-Salem, North Carolina

  • University of Cincinnati Physicians Company

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Boster Center for Multiple Sclerosis

    Columbus, Ohio

  • Neurology Clinic, PC

    Cordova, Tennessee

  • Vanderbilt MS Center

    Nashville, Tennessee

  • The University of Texas Health Science Center San Antonio

    San Antonio, Texas

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

  • The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • 'MHAT Avis - Medica' OOD

    Pleven, Bulgaria

  • UMHAT 'Dr. Georgi Stranski', EAD

    Pleven, Bulgaria

  • UMHAT 'Sv. Georgi', EAD

    Plovdiv, Bulgaria

  • MHATNP 'Sv.Naum', EAD

    Sofia, Bulgaria

  • University First MHAT-Sofia, 'St. Joan Krastitel' EAD

    Sofia, Bulgaria

  • Acibadem City Clinic Tokuda University Hospital Ead

    Sofia, Bulgaria

  • DCC Neoclinic EAD

    Sofia, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, Bulgaria

  • Diagnostic Consultation Center CONVEX EOOD

    Sofia, Bulgaria

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Nemocnice Jihlava p.o.

    Jihlava, Czechia

  • Fakultni Thomayerova nemocnice

    Praha 4-Krc, Czechia

  • Krajska zdravotni a.s. - Nemocnice Teplice o.z.

    Teplice, Czechia

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, Germany

  • Studienzentrum fur Neurologie und Psychiatrie

    Böblingen, Baden-Wurttemberg, Germany

  • Klinikum Bayreuth GmbH- Hohe Warte

    Bayreuth, Bavaria, Germany

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.